WallStSmart
ATRA

Atara Biotherapeutics Inc

NASDAQ: ATRA · HEALTHCARE · BIOTECHNOLOGY

$9.81
-3.41% today

Updated 2026-06-05

Market cap
$86.77M
P/E ratio
P/S ratio
3.75x
EPS (TTM)
$-1.22
Dividend yield
52W range
$4 – $19
Volume
1.7M

Atara Biotherapeutics Inc (ATRA) Financial statements

SEC filings — annual and quarterly data.

Profit margin
27.07%
Operating margin
29.69%
ROE
-2,015.00%
ROA
11.10%
Debt/equity
-0.27x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2012$-123.30M
2013$-87.73M
2014$0.00$-28.01M
2015$0.00$-57.22M
2016$0.00$-79.05M
2017$0.00$-119.49M
2018$0.00$-230.70M
2019$0.00$-290.98M
2020$3.55M$-306.62M-277.79%-8,700.79%-8,632.32%
2021$20.34M$-340.14M100.00%-1,673.85%-1,672.28%
2022$63.57M$-228.30M100.00%-441.25%-359.12%
2023$8.57M$-276.13M-3.65%-3,219.48%-3,220.88%
2024$128.94M$-85.40M83.71%-64.71%-66.23%
2025$120.77M$32.69M82.44%29.69%27.07%

Frequently asked questions

What is Atara Biotherapeutics Inc's revenue?

Atara Biotherapeutics Inc's trailing twelve-month revenue is $23.14M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ATRA?

In its most recent fiscal year, ATRA ran a gross margin of 82.44%, an operating margin of 29.69%, and a net margin of 27.07%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ATRA generate?

ATRA produced $-50.94M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ATRA's balance sheet healthy?

ATRA holds $8.48M in cash and equivalents against — in long-term debt, on $-38.50M of shareholder equity. That debt is best read against the cash flow the business throws off each year.